TL;DR
UK sales of hair loss products grew 32% in the year to the end of August, while reported household use of GLP-1 drugs also rose. A BMJ study identified an association between GLP-1 medicines and increased hair-loss risk, which researchers described as low in absolute terms. Novo Nordisk has announced plans to enter the hair-loss treatment market, but details of its plans were not provided in the source report.
UK sales of hair-loss products rose 32% in the year to the end of August, according to Worldpanel by Numerator, amid a sharp rise in household use of GLP-1 medicines and new research linking the drugs with a higher risk of hair loss. The association has also drawn pharmaceutical maker Novo Nordisk toward the hair-loss treatment market, though the source report gives no details of its plans.
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Worldpanel by Numerator estimates that use of GLP-1 medicines in Great Britain reached 6.3% of households in 2026, up from 4.1% in 2025 and 2.3% in 2024. The figures cover household use of medicines including semaglutide and tirzepatide, sold under brand names such as Ozempic, Wegovy and Mounjaro. They do not show what share of individual users experience hair loss.
A recent study published in the British Medical Journal identified an association between GLP-1 drugs and increased risk of hair loss. The researchers said the absolute risk is low, and that awareness of the possible effect may help inform treatment decisions. The source report does not provide the study’s sample size, the size of the relative risk, or details on how risk varied by medicine or patient.
Hair-thickening, volumising and strengthening products, as well as treatments for thinning and hair loss, predate the rise in GLP-1 use. Worldpanel’s 32% sales estimate is a market measure; the report says the acceleration is likely correlated with increased use of the medicines, but does not establish that GLP-1 use caused the sales growth. Novo Nordisk, maker of Ozempic, has announced an intention to enter the hair-loss treatment arena, according to the report.
Hair Loss Enters GLP-1 Decisions
The findings put a potential side effect into a growing conversation around medicines used for weight loss and other health needs. The BMJ study’s reported association may be relevant to discussions between patients and clinicians, while its low absolute-risk assessment gives important scale: the source does not indicate that hair loss is common among all users.
The market response is also becoming visible. Higher sales of hair-loss products point to increased commercial interest, and Novo Nordisk’s stated intention suggests a drugmaker sees a possible opportunity. Neither development establishes which products work for GLP-1-associated shedding or whether the sales increase is mainly driven by medicine use.
Products Worth Considering

Withings Sleep Under-Mattress Sleep Tracking Pad

Oral-B iO3 Rechargeable Electric Toothbrush with 3 Cleaning Modes, Pressure Sensor, 2 Brush Heads and Travel Case, White

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band
As an affiliate, we earn on qualifying purchases.
Use and Product Sales Rise
GLP-1 medicines include semaglutide and tirzepatide. The source report describes their use in Great Britain as having moved into the mainstream and cites Worldpanel household estimates rising from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. These are household figures, not a count of prescriptions or a measure of how long people have taken the medicines.
Hair care has long included products marketed for volume, thickness and strength, alongside treatments aimed at hair loss and thinning. The recent development is the overlap between that established category, growing GLP-1 use and new research on a possible hair-loss association. The source report links these trends but does not show that one directly caused the other.
“The absolute risk is low.”
— Researchers in the BMJ study, as summarized by Cosmetics Business
Study and Market Links Remain Unclear
The source report does not give the BMJ study’s methods, participant numbers, or the magnitude of the risk increase. It also does not establish whether hair loss is directly caused by the medicines, related to weight loss or other factors, or different across specific drugs and patients. The researchers’ description of low absolute risk should be read alongside those missing details.
The reason for the 32% increase in UK hair-loss product sales has not been established. Worldpanel’s estimate and the rise in household GLP-1 use coincide, but the available material does not show what portion of sales growth is attributable to medicine users. Novo Nordisk’s proposed entry is also short on specifics: no product, timetable, or development status is stated.
More Detail Needed on Treatments
Further published details on the BMJ study would clarify the scale of the association and the groups it covers. More information from Novo Nordisk would show whether its stated intention involves research, development, or a planned launch. New market data could also help determine whether hair-loss product sales continue to rise and how much of that trend is linked to GLP-1 use.
Key Questions
What did the BMJ study find?
It identified an association between GLP-1 drugs and an increased risk of hair loss. Researchers described the absolute risk as low; the source report does not include the study’s detailed risk estimates.
How much did UK hair-loss product sales grow?
Worldpanel by Numerator estimated growth of 32% in the year to the end of August. The source does not establish what caused the increase.
How common is GLP-1 use in Great Britain?
Worldpanel’s household estimate rose from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. These figures measure households, not individual users.
Is Novo Nordisk launching a hair-loss treatment?
The report says the Ozempic maker announced an intention to enter the hair-loss treatment market. It gives no product details or launch timetable, so a specific treatment launch is not confirmed by the supplied material.
Source: rss
